In the PRONOUNCE trial [22], which compared the cardiovascular safety of a GnRH agonist and antagonist, a cardiologist ensured that baseline secondary prevention medications for atherosclerotic cardiovascular disease (ASCVD) were optimized according to the guideline recommendations, but systematic coronary evaluation were not performed. This evidence concerns the gene GNRH1 and atherosclerosis.